SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask
1
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
As soon as the first case of the omicron variant of severe acute respiratory syndrome coronavirus 2 was reported in November 2021, it quickly spread worldwide with the emergence of several subvariants. Compared to previous variants, omicron was heavily mu tated, especially for those in the Spike (S) protein and its receptor-binding domain. These mutations allowed the viruses to evade immune responses (i.e., previous infections and vaccine-elicited) and increase in transmissibility. Although vaccine effectiveness is decreased for omicron, boosters remain effective for protecting against severe diseases. Also, bivalent vaccines have been devel oped to increase vaccine effectiveness. Interestingly, although omicron is highly infectious, it has less morbidity and mortality compared to previously identified variants, such as delta. Additionally, the mutations that allow the virus to evade immune re sponses also allow it to evade many of the monoclonal antibodies developed at the beginning of the pandemic for treatment. Here, we reviewed the omicron variant’s epidemiology, genetics, transmissibility, disease severity, and responsiveness to vaccine and treatments.
Abstract
As soon as the first case of the omicron variant of severe acute respiratory syndrome coronavirus 2 was reported in November 2021, it quickly spread worldwide with the emergence of several subvariants. Compared to previous variants, omicron was heavily mu tated, especially for those in the Spike (S) protein and its receptor-binding domain. These mutations allowed the viruses to evade immune responses (i.e., previous infections and vaccine-elicited) and increase in transmissibility. Although vaccine effectiveness is decreased for omicron, boosters remain effective for protecting against severe diseases. Also, bivalent vaccines have been devel oped to increase vaccine effectiveness. Interestingly, although omicron is highly infectious, it has less morbidity and mortality compared to previously identified variants, such as delta. Additionally, the mutations that allow the virus to evade immune re sponses also allow it to evade many of the monoclonal antibodies developed at the beginning of the pandemic for treatment. Here, we reviewed the omicron variant’s epidemiology, genetics, transmissibility, disease severity, and responsiveness to vaccine and treatments.
참고문헌 (42)
- 최준용, "SARS-CoV-2 Variants of Concern", Yonsei Medical Journal, 62(11), pp.961~968 (2021), 연세대학교의과대학[DOI]
- [URL]
- "Weekly epidemiological update on COVID-19 - 20 July 2022"[URL]
- Kandeel M, "Omicron variant genome evolution and phylogenetics", J Med Virol, 94, pp.1627~1632 (2022)
- Sun C, "Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants", Signal Transduct Target Ther, 7, pp.202~ (2022)
- Du Z, "Reproduction numbers of severe acute respiratory syndrome coronavirus 2(SARSCoV-2)variants : a systematic review and meta-analysis", Clin Infect Dis, 75, pp.e293~e295 (2022)
- Campbell F, "Increased transmissibility and global spread of SARSCoV-2 variants of concern as at June 2021", Euro Surveill, 26, pp.2100509~ (2021)
- Thakur V, "OMICRON (B.1.1.529): a new SARS-CoV-2 variant of concern mounting worldwide fear", J Med Virol, 94, pp.1821~1824 (2022)
- Ren SY, "Omicron variant(B. 1. 1. 529)of SARS-CoV-2 : mutation, infectivity, transmission, and vaccine resistance", World J Clin Cases, 10, pp.1~11 (2022)
- Kumar S, "Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: a comparative sequence and structuralbased computational assessment", J Med Virol, 94, pp.4780~4791 (2022)
- Tuekprakhon A, "Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum", Cell, 185, pp.2422~2433 (2022)[DOI]
- "Neutralization sensitivity of Omicron BA.2.75 to therapeutic monoclonal antibodies" (2022)[URL]
- Maslo C, "Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves", JAMA, 327, pp.583~584 (2022)
- "Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron" (2022)[URL]
- Sheikh A, "Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland(EAVE II) : a national cohort study with nested test-negative design", Lancet Infect Dis, 22, pp.959~966 (2022)
- Zhao H, "SARSCoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells", Emerg Microbes Infect, 11, pp.277~283 (2022)
- Hui KPY, "SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo", Nature, 603, pp.715~720 (2022)
- Meng B, "Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity", Nature, 603, pp.706~714 (2022)
- Suzuki R, "Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant", Nature, 603, pp.700~705 (2022)
- Keeton R, "T cell responses to SARS-CoV-2 spike cross-recognize Omicron", Nature, 603, pp.488~492 (2022)
- "Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5" (2022)[URL]
- "Weekly epidemiological update on COVID-19 - 11 January 2022"[URL]
- Grabowski F, "The spread of SARSCoV-2 variant Omicron with a doubling time of 2. 0-3. 3 days can be explained by immune evasion", Viruses, 14, pp.294~ (2022)
- Liu Y, "The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta", J Travel Med, 29, pp.taac037~ (2022)
- [URL]
- [URL]
- Carreño JM, "Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron", Nature, 602, pp.682~688 (2022)
- Hachmann NP, "Neutralization escape by SARS-CoV-2 omicron subvariants BA. 2. 12. 1, BA. 4, and BA. 5", N Engl J Med, 387, pp.86~88 (2022)
- Flacco ME, "Risk of reinfection and disease after SARS-CoV-2 primary infection : meta-analysis", Eur J Clin Invest, 52, pp.e13845~ (2022)
- Barda N, "Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel : an observational study", Lancet, 398, pp.2093~2100 (2021)
- Altarawneh HN, "Effects of previous infection and vaccination on symptomatic omicron infections", N Engl J Med, 387, pp.21~34 (2022)
- Bar-On YM, "Protection by a fourth dose of BNT162b2 against Omicron in Israel", N Engl J Med, 386, pp.1712~1720 (2022)
- [URL]
- "Emergency use authorization"[URL]
- [URL]
- Chalkias S, "A bivalent Omicron-containing booster vaccine against COVID-19", N Engl J Med, 387, pp.1279~1291 (2022)
- VanBlargan LA, "An infectious SARS-CoV-2 B. 1. 1. 529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies", Nat Med, 28, pp.490~495 (2022)
- Westendorf K, "LY-CoV1404(bebtelovimab)potently neutralizes SARSCoV-2 variants", Cell Rep, 39, pp.110812~ (2022)
- Takashita E, "Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant", N Engl J Med, 386, pp.995~998 (2022)
- Sheward DJ, "Evasion of neutralising antibodies by omicron sublineage BA. 2. 75", Lancet Infect Dis, 22, pp.1421~1422 (2022)
- Yamasoba D, "Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies", Lancet Infect Dis, 22, pp.942~943 (2022)
- Vangeel L, "Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern", Antiviral Res, 198, pp.105252~ (2022)